Combined Multi-marker Screening and Treatment With Aspirin for Pre-eclampsia Prevention

PHASE3CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Preeclampsia
Interventions
DRUG

Aspirin

"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."

DRUG

Placebo

"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."

Trial Locations (1)

Unknown

Rabin Medical Center, Petah Tikva

All Listed Sponsors
collaborator

University College, London

OTHER

lead

Rabin Medical Center

OTHER

NCT02301780 - Combined Multi-marker Screening and Treatment With Aspirin for Pre-eclampsia Prevention | Biotech Hunter | Biotech Hunter